摘要
[目的]①通过观察慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)急性加重期轻、中、重三组病人的血清白细胞介素-6 (interleukin-6, IL-6),FKN趋化因子(fractalkine, FKN或CX3CL1)的水平,探讨细胞因子IL-6、FKN在COPD疾病进展中的关系；②通过测量患者的肺功能,探讨患者血清IL-6、FKN的水平与肺功能的关系。
[方法]选取79例诊断为COPD的呼吸内科住院病人,且为急性加重期,排除混杂因素后,行肺功能检查后根据第一秒用力呼气容积%预计值(forced expiratory volume in one second% predicted, FEV1%Pre),分为轻、中、重三组,其中轻度患者28例,中度患者28例,重度患者23例。并于住院次日清早空腹抽取患者静脉血,测定血清IL-6和FKN的水平。
[结果]
①急性加重期的COPD的轻、中、重三组病人血清的IL-6, FKN的水平,经统计学分析后P<0.01,差异有统计学意义,三组病人中血清IL-6、FKN的水平不等；
②行两两比较后,三组病人的IL-6的水平都不相同,且重度病人的IL-6的水平最高,中度病人的IL-6的水平次之,轻度病人的IL-6的水平最低,各组间比较,P值小于0.05；轻度组与中度组FKN比较时,P<0.05,差异有统计学意义,中度高于轻度；轻度组与重度组比较时,P<0.05,差异有统计学意义,重度高于轻度；中度组和重度组比较时,P>0.05,差异无统计学意义；
③患者血清IL-6、FKN与患者肺功能(FEV1%预计值)的相关性研究发现：FEV1%预计值随着IL-6的水平的升高而降低,P=0.000,r=-0.877,说明IL-6与FEV1%预计值存在负相关关系；FEV1%预计值随着FKN的水平的升高而降低,P=0.000,r=-0.584,说明FKN与FEV1%预计值也存在负相关关系。
[结论]
1.检测COPD患者血清中细胞因子的水平,有助于进一步研究细胞因子在COPD发病机制中的作用。
2. COPD急性加重期轻、中、重三组病人血清IL-6的不同表达、IL-6的水平与FEV1%预计值的相关性可能说明：病情越重,IL-6的水平越高,炎症反应也越严重,患者的肺功能就越低。
3. COPD急性加重期轻、中、重三组病人血清FKN的不同表达、FKN的水平与FEV1%预计值的相关性可能说明：FKN与COPD的发展可能有一定的关系,随着FKN的升高,患者肺功能有下降的趋势,但是,在中、重度病人中FKN的差异无统计学意义,可能说明：当COPD发展到一定程度(中、重度)后,FKN的表达无太大的变化,而可能与病人发展为更严重的疾病有关,如：肺动脉高压,肺心病等。
[Objectives]①To investigate the changes of serum interleukin -6(IL-6) fractalkine(FKN or CX3CL1) levels in chronic obstructive pulmonary disease(COPD) with acute exacerbation of mild、moderate and severe group of patients,explore the relationship between levels of cytokines IL-6、FKN and disease progression in COPD②By measuring the patient's lung function of patients, explore the relationship between levels of serum IL-6、FKN and the level of lung function.
[Methods] Selected the 79 patients hospitalized in the respiratory department of patients were diagnosed with COPD, and acute exacerbation of.Excludeed confounding factors, lined after the pulmonary function tests forced expiratory volume in one second% predicted (FEV1%Pre) were divided into mild、moderate and severe groups,28 patients with mild,28 patients with moderate,23 patients with severe. And extracted the second day of fasting morning blood of patients, masured serum levels of IL-6 and FKN.
[Results]
①Acute exacerbation of COPD mild、moderate and severe group of patients serum IL-6、FKN levels, by statistical analysis,P<0.01, there were significant differences, three groups of patients in the serum IL-6 FKN unequal level;
②Comparison between two lines, three groups of patients the level of IL-6 is not the same, and severe patients the highest levels of IL-6, patients with moderate levels of IL-6 in the second highest, patients with mild levels of IL-6 minimum, The comparison between groups.P values were less than 0.05; when compared between mild and moderate group of FKN, P<0.05, statistically significant differences,higher than the mild to moderate. when compared between mild group and severe group, the P<0.05, statistically significant differences, higher than the mild to severe, when compared between moderate group and severe group P>0.05, the difference was not statistically significant;
③Serum IL-6、FKN of patients correlation with pulmonary function (forced expiratory volume in one second%predicted)findings:FEV1% predicted decrease with the levels of IL-6 increase,P=0.000,r=-0.877, that IL-6 and FEV1% predicted a negative correlation; FEV1% predicted decrease with the level of FKN increase,P=0.000,r=-0.548, that FKN and FEV1% predicted negative correlation exists.
[Conclusions]
1.Measured of COPD patients levels of serum cycokines, contribute to the further study of cytokines in the pathogenesis of the role of COPD.
2. COPD with acute exacerbation of mild, moderate and severe group of patients the difference in serum IL-6 expression,IL-6 levels and FEV1% predicted correlation may indicate:More severe disease, IL-6 levels higher, the more severe inflammatory response,lower lung function in patients.
3.COPD with acute exacerbation of mild, moderate and severe groups of different serum FKN expression,FKN levels and FEV1% predicted correlation may indicate: FKN and the development of COPD may have some relationship, with the increase of FKN, a downward trend in pulmonary function, however, in moderate to severe patients no significant differences in FKN, may indicate:when developed to a certain degree of COPD (moderate and severe) after, FKN expression was not much change, and patients may develop more serious diseases,such as:pulmonary hypertension, pulmonary heart disease and so on.
引文
[1]中华医学会呼吸病学会分会.慢性阻塞性肺疾病诊断指南[J].中华结核和呼吸杂志,2007,30(1)：8-17.
[2]叶任高等主编.《内科学》.第6版.北京：人民卫生出版社,2004.1：57-63.
[3]Bames PJ,shaPiro SD, Pauwels RA.chronic obstructive pulmonary disease mole cular and cellular mechanisms[J].EurRespir 2003,22(4):672-688.
[4]Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am JResp ir Crit CareMed,2006,173 (9):991 998.
[5]Sethi S. Bacteria in Exacerbations of Chronic Obstructive Pulmonary Disease Phenomenon or Epiphenomenon? Proc Am Thorac Soc,2004,1 (2):109-114.
[6]Chin CL, ManzelLJ, Lehman EE, et al. Haemophilus influenzae from COPD patient swith exacerbation induce more inflammation than colonizers. Am J Resp ir Crit CareMed,2005, 172(1):85-91.
[7]李成海,邹国华,马利军,等.老年慢性阻塞性肺疾病细胞免疫功能的初步探索.河南医药信息,2001,9(5)：7-9.
[8]Barnes PG, Chowdhury B, Kharitonov SA. et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Resp ir Crit CareMed,2006,174 (1):6-14.
[9]Yasuda N, Gotoh K,Minatoguchi S, et al. An increase of soluble Fas. An inhibitor of apop tosis. associated with progression of COPD. Resp irMed,1998,92 (8):993-999.
[10]王冰云.中国免疫学杂志,1977,13：5-8.
[11]Jin XL,Zimmers TA, Perez EA, et al. Para doxical effects of short- nd long-term inter leukin-6 exposure on liver injury and repair [J]. Hepatology,2006,43 (3):474-484.
[12]Yamashita T, Sawamoto S, Suzuki S, et al.Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice:possible involvement of Stat3 activation in the protection of neurons [J]. J Neurochem,2005,94 (2):459-468.
[13]EckerM,M uller G. Cytok ine release after administration of endotoxin containing vaccines [J]. ALT EX,1998,15:68-71.
[14]M eyer TA, W ang J, Tiao GM, et al. Sep sis and endotoxem ia stimulate intestinal interleuk in-6 production[J]. Surgery,1995,118 (2):336-342.
[15]袁志明.白细胞介素6与呼吸系统疾病[J].国外医学呼吸系统分册,1997,17(1)：33-35.
[16]莫丽亚,.赵蕊,叶志纯,朱纯华.急性感染患者血清肿瘤坏死因子、白介素-6和C反应蛋白水平的比较.中国现代医学杂志,2000,8(8)：10.
[17]濮跃晨.全自动血培养系统检测730份分析[J].中华检验医学杂志,2000,23(2)102.
[18]孟涛.胃病患者血清Hp抗体与CRP的相关性探讨[J].实用医技杂志.,2006,13(4)545.
[19]杨恂,官和立,姚薇等.检测慢性支气管炎患者血清、痰中白细胞介素及C反应蛋白的临床意义[J].临床内科杂志,2003,20(10)：539.
[20]Anderson GP. COPD, asthma and C-reactive protein. Eur Resp ir J,2006,27 (5):874-876.
[21]Keating VM,collins PD scottDM,et al.Differences in interleukin-8 and tumor necrosis factor-apha in induced sputum from patients with chronic obstructive pulmonary disease or asthma [J].Am J Respir Crit Care Med 1996,153(2):530-534.
[22]Bazan JF,Bacon KB,Hardiman G,et al.A new class of membranebound chemokine with a CX3C motif.Nature 1997,385;640-644.
[23]Haskell CA, Cleary MD, Charo IF, et al. Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion[J]. J BiolChem,2000,275 (44):34183-34189.
[24]Foussat A, CoulombL,Hermine A, Gosling J, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human[J]. Eur J Immunol,2000,30 (1):87-97.
[25]Lucas AD, Chadwick N, Warren BF, et al. The transmembrane formofthe CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo[J]. AmJ Pathol,2001,158 (3):855-866.
[26]Balabanian K, Foussat A,Forfmuller P,et al.CXC3 chemokine fractalkine in pulmonary arterial hypertension.Am J Respir Crit Care Med,2002,165; 1419-1425.
[27]Kunkel SL,Lukacs NW, Strieter RM,et al.The role of chemokines in the immunopathology of pulmonary disease.Forum (Genova),1999,9;339-355.
[28]Sukkar MB,Issa R, Xie S,et al. Fractalkine/CX3CL1 production by human airway smooth muscle cells:induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and couticosteroids.Am J Physiol Lung cell Mol physial,2004,287;L1230-1240.
[29]Fujimoto K,Imaizumi T, Yoshida H,et al. Interfern-gamma stimulates fractalkine expression in human bronchial epithlial cells and regulates,mononuclear cell adherence [J].Am J Respir Cell MolBiol,2001,25(2):233-238.
[30]Roland M, Bhownik A,sapsford RJ, et al. sputum and plasma endothelia-1 leves in erbations of chronic obstructive of chronic obstructive pulmonary disease [J].Thorax,2001,56(1);30-35.
[31]陈小菊,程德云,杨莉等.缺氧大鼠血清和肺内Fractalkine的变化.中华结核和呼吸杂志,2006,29：54-55.
[32]金敬顺,陈正堂.单核/巨噬细胞释放的趋化因子与急性肺损伤[J].国外医学呼吸系统分册,1997,17：133-136.
[33]彭则,张永兴.肺泡巨噬细胞对呼吸道免疫炎症性反应的影响[J].国外医学呼吸系统分册,1997,17：33-38.
[34]Ridker PM,Rifai N,Stampfer MJ,et al.Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.Circulation,2000,101 (15):1767-1772.
[35]Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity. Front Biosci,2008.13:1227-12239.
[36]Hong DS,Angelo LS, Kurzrock R.Interleukin-6 and its receptor incancer:implications for translational therapeutics. Cancer,2007,110 (9):1911-1928.
[37]Paule B, Terry S, KheuangL, et al. The NFkappaB/IL-6 pathway inmetastatic androgen independent prostate cancer:new therapeuticapp roaches?World J Urol,2007,25 (5) 477-489.
[38]史继静,刘朝奇.白介素6与肿瘤相关性的研究进展.生命的化学,2008,28(160)：12.
[39]Nibali L, Griffiths GS, Donos N, et al. Association between interleukin- 6 promoter haplotypes and aggressive periodontitis[J]. J Clin Periodontol,2008,35(3):193-198.
[40]刘文彬,涂冬梅,袁丽,等.肺炎支原体肺炎IL- 2 sIL- 2R IL- 6 IL- 8动态变化及临床意义[J].西南国防医药,2006,16(1)：32-33.
[41]Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma:Similarities and differences[J]. Respirology,2008,13(1) 128-133.
[42]Bhowmik A,Seemungal TA,sapsford RJ,et al. Relation of sputum inflammatory markers to symptoms and lung faction changes in COPD exacerbations.Thorax,2000,55:114-120.
[43]Roland M, Bhownik A,sapsford RJ, et al.sputum and plasma endothelia-1 leves in erbationsof chronic obstructive pulmonary disease[J].Thorax,2001,56(1):30-35.
[44]Kemeny DM,VyasB,VukmanovicstejicM, et al. CD8+T Cell Subsets and Chronic Obstructive Pulmonary Disease. American Journalof Resp iratory and Critical CareMedicine,1999,160 (5):33.
[45]DE BOER W I. Cytokines and therapy in COPD. Chest,2002,121:209-218.
[46]Soler N, Ew ig S, To rresA, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur2Resp ir I,1999,14 (5) 1015.
[47]黎东明,陈琼,何惠娟,等.慢性阻塞性肺疾病发病中的中性粒细胞凋亡作用研究.中国基层医药,2005,12(5)：517-519.
[48]刘景艳,修清正.细胞因子在慢性阻塞性肺疾病发病中的作用.国外医学呼吸系统分册,2005,25(6)：420-422.
[49]Mo rrison DF, Fo ss DL, M uraugh M P. Interleukin-10 gene therapymediated a melio rat ion of bacterialpneumonia. InfectImmun,2000,68 (8):475.
[50]李玉珊.慢性阻塞性肺病合并肺部感染患者IL-6、IL-8、TNF-a测定的临床意义.医学文选.2003,22：636-637.
[51]刘艳红,夏熙郑IL-6, Fas与慢性阻塞性肺疾病急性加重期的相关性研究.中国实用医药2009,4(2)：19-21.
[52]Suwa T,English D,Hogg JC,et al. The effect of interleukin-6 on polymor phonuclear leukocytes in the circulation and bone marrow[J]. AmJ RespirCrit Care Med,2000,161:A684.
[53]Suwa T,Hogg JC,English D,et al. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow[J]. Am JPhysiol Heart Circ Physiol,2000,79 (6):9542-960.
[54]Bazan JF, Bacon KB, Hardiman G, et al. Nature,1997,385:640-644.
[55]Umehara H,Bollm ET,okazaki T, et al. Fractalkine and vascular injury [J].Trends immunol,2001,22(11):602-607.
[56]Kimura H,Kasahara Y,Kurousu K,et al.Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoatractant protein-I.Lab Invest,1998,78:571-58.
[57]EL-Shazly A,Berger P,Girodet PO,et al. Fractalkine produced by airway smooth muscle cells contributes to mast cell recritment in asthma.J Immunol.2006,176:1860-1868.
[58]Perros F,Dorfmuller P,Souza R,et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension,Eur Respir J,2007,29:937-943.
[59]Tremblay K,Lemire M,Provost V,et al.Association study between the CX3CR1 gene and asthma.Genes Immun,2006,7:632-639.
[60]郑碧霞,程德云,陈小菊,等.低氧性肺动脉高压大鼠肺内Fractalkine的变化[J].四川大学学报(医学版),2008,39(2)：227-230.
[61]陈小菊,程德云,杨莉,等.低氧性肺动脉高压大鼠肺内Fractalkine的变化[J].四川大学学报(医学版),2007,38(5)：756-760.
[62]张晓鸣,陆超,赵鹏程,等.分泌型白细胞蛋白酶抑制剂对急性肺损伤大鼠趋化因子Fractalkine表达的影响[J].江苏大学学报(医学版),2007,17(4)；302-308.
[63]Ito Y,Kawachi H,Morioka Y,et al. Fractalkine expression and the recruitment of CX3CR1-cells in the prolonged mesangial proliferative glomerulonephritis [J].Kid Int,2002,61(67):2044-2057.
[64]Schafer A,Bauersachs J.Endothelial dysfunction, impaired endogenous platelet altivation in diabetes and atherosclerosis[J].Curr Vasc Pharmacol,2008,6(1):52-60.
[65]Goda S,Imai T,Yoshie O,et al. CXC-chemokine, Fractalkine-enhanched adhension of THP-1 cells to endothlial cells through integrin-dependent and independent mechanisms.J Immunol,2000,164:4313-4323.
[66]Marasini B,Cossutta R,Selmi C,et al. Polymorphism of fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension.Clin Dev Immunol,2005,12:275-279.
[1]中华医学会呼吸病学会分会.慢性阻塞性肺疾病诊断指南.中华结核和呼吸杂志,2007,30：8-17.
[2]Bames PJ,shaPiro SD, Pauwels RA. Chronic obstructive pulmonary disease mole cular and cellular mechanisms.Eur Respir J,2003,22:672-688.
[3]袁志明.白细胞介素6与呼吸系统疾病.国外医学呼吸系统分册,1997,17：33-35.
[4]Keating VM,collins PD,scott DM,et al.Differences in interleukin-8 and tumor necrosis factor-apha in induced sputum from patients with chronic obstructive pulmonary disease or asthma.Am J Respir Crit Care Med,1996,153:530-534.
[5]Bhowmik A,Seemungal TA,sapsford RJ,et al.Relation of sputum inflammatory markers to symptoms and lung fuction changes in COPD exacerbations.Thorax,2000,55: 114-120.
[6]Roland M, Bhownik A,sapsford RJ, et al. Sputum and plasma endothelia-1 leves in erbationsof chronic obstructive pulmonary disease.Thorax,2001,56:30-35.
[7]朱哗涵,蒋军红,黄建安.哮喘、慢性阻塞性肺疾病(COPD)急性加重期患者痰中炎性标志物变化及与肺功能的关系研究.苏州大学学报(医学报),2005,25：317-319.
18] Wymann MP, von Tscharner V,Deranleau DA,et al.The onset of the respiratory burst in human neutrophils.Real-time studies of H2O2 fromation reveala rapidagonist induced transduction process.Jbio Chem,1987,262:12048-12053.
[9]Detmers PA,Lo Sk,Olsen-Egbert E,et al.Eutrophil-activating protein inter leukin 8 stimulates the binding activity of the leukocytee adnesion receptor CDllb/CD18 on human neutrophics. J Exp Med,1990,171:1555-1162.
[10]Peng DW,Huang,HY,Chen HM, et al.Characteristics of airway inflammation and bronchodilator reversibility in COPD:a potential guide to treatment Chest,2004,126: 375-381.[11]刘笑然,丁春华,叶琳,等.慢性阻塞性肺疾病患者血清细胞因子与肺功能相关性研究.中国热带医学,2007,7：1546-1547,1549.[12] Venkayya R,Lam M,Willkom M,et al.The Th2 lymphocyte products IL-4 and IL-13 rapidaly induce airway hyper responsiveness through direct effect on resident airway cells. Am J Respir cell Mol Biol,2002,262:202-208.
[13]Striz I Mio T,Adachi Y,et al.IL-4 and IL-13 stimulate human bronchial epithelial cells to release IL-8, Inflammation,1999,23:545-555.
[14]Zheng T,Zhu Z,Wang Z,et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinas and cathepsim dependent emphysema.J Clin Invest,2006,106: 1081-1093.
[15]王丽慧,曹作炎.老年慢性阻塞性肺疾病血清白细胞介素-13的变化.临床内科杂志,2003,20：586-588.
[16]Laan M,Lotvau J,Chung KF,et al.IL-17 induced cytokine release in human bronchial epitheliva cells in vitro:role of mitogen activated protein (MAP) kinases. Br J Pharmacol,2001,133:200-206.
[17]Molet S, Hamid Q,Davoine F,et al.IL-7 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunal,2001,108: 430-438.
[18]Semik-Orzech A,Barczyk A,PierzchalaW.The role of interleukin 17A in inducing neutrophilic inflammaton in the pulmonary tract,Pol Merkur LeKarski,2007,22:163-168.
[19]王妹芳,王龙武,邓星奇.慢性阻塞性肺疾病患者外周血及痰中IL-8, IL-17及TGF-B水平的检测和意义.经验医学,2007,22：394-397.
[20]龚燕,金美玲,任涛,等.血清干扰素-γ及白细胞介素-2,4,5,10与慢性阻塞性肺疾病的关系.上海医学,2008,31：474-476.
[21]曾勉,刘凌云,王辉,等.慢性阻塞性肺疾病患者痰中TNF-α及其受体水平与气流受限的关系.中山大学学报(医学科学版),2008,29：82-86.
[22]Aarons SD,Angel JB,Lunau M, et al.Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease.Am J Respir Crit Care Med,2001,163:349-355.
[23]Beeh KM, Kommann O, Buhl R,et al. Neutrophil chemotactic activity of sputum from patients with COPD; role ofinterleukin 8 and leukotriene B4.Chest,2003,123: 1240-1247.
[24]Thompsom AB,Daughtom D,Robbins RA,et al.Intraluminal airway inflammation chronic bronchitis; Charaterization and correlation with clinical parameter.Am Rev Respir Dis 1989,140:1527-1537.
[25]阎蘅.慢性阻塞性肺疾病急性加重期与缓解期血清白介素-8,肿瘤坏死因子a变化.中国医刊,2008,43：42-43.
[26]牟小芬,陈素娟,蔡力力,等.老年慢性阻塞性肺疾病缓解期T淋巴细胞值与细胞因子浓度.标记免疫分析与临床,2006,13：73-74,80.